[Skip to Content]
[Skip to Content Landing]
Views 2,505
Citations 0
Editorial
June 18, 2019

Putting the New Alzheimer Disease Amyloid, Tau, Neurodegeneration (AT[N]) Diagnostic System to the Test

Author Affiliations
  • 1Department of Neurology, University of Pennsylvania, Philadelphia
  • 2Departments of Psychiatry and Neurology, Alpert Medical School, Brown University, Providence, Rhode Island
  • 3Frontotemporal Disorders Unit & Alzheimer’s Disease Research Center, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston
JAMA. 2019;321(23):2289-2291. doi:10.1001/jama.2019.7534

The field of neurodegenerative dementias, particularly Alzheimer disease (AD), has been limited by challenges in accurate diagnosis, but has recently been potentially revolutionized by the development of imaging and cerebrospinal fluid (CSF) biomarkers. These biomarkers have influenced the diagnostic evaluation of symptomatic patients with cognitive impairment or dementia, particularly in dementia subspecialty practice. The primary biomarker modalities include magnetic resonance imaging (MRI), positron emission tomography (PET), and CSF.

×